Improving pertusis vaccination

Human Vaccines

Volumn 5, Issue 7, 2009, Pages 497-503

  Berbers, Guy A M ^a   de Greeff, Sabine C ^a   Mooi, Frits R ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

(Waning) immunity; Antigenic variation; Bordetella pertusis; Vaccination strategy; Vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PEDIACEL; PENTACEL; PENTAVAC; PERTUSSIS VACCINE; QUADRACEL; TETRAVAC; TRIPACEL; UNCLASSIFIED DRUG;

ARTICLE; AWARENESS; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; MATERNAL CARE; MATERNAL TREATMENT; NEWBORN CARE; PERTUSSIS; POLYMERASE CHAIN REACTION; SEROLOGY; UNSPECIFIED SIDE EFFECT; VACCINE FAILURE; VACCINE PRODUCTION; WHOLE CELL; DEVELOPED COUNTRY; HETEROZYGOTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; REVIEW; UTILIZATION REVIEW; VACCINATION;

BORDETELLA PERTUSSIS; CARRIER STATE; DEVELOPED COUNTRIES; HUMANS; IMMUNIZATION, SECONDARY; PERTUSSIS VACCINE; VACCINATION; WHOOPING COUGH;

EID: 70349535979     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.8112     Document Type: Article

References (104)

1. Mooi FR, He Q, Guiso N. Phylogeny, Evolution and Epidemiology of Bordetellae. In: Locht C, ed. Bordetella Molecular Microbiology. First ed. Horizon Bioscience, Norfolk UK 2007; 17-45.
2. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol 2008; 3:329-39.
3. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 2006; 367:1926-36.
4. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006; 53:106-13.
5. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115:1422-7.
6. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of Acellular Pertussis Preschool Booster Vaccination on Disease Burden of Pertussis in The Netherlands. Pediatr Infect Dis J 2008; 27:218-23.
7. Riffelmann M, Littmann M, Hulsse C, O'brien J, Wirsing von Konig CH. Pertussis: incidence, symptoms and costs. Dtsch Med Wochenschr 2006; 131:2829-34.
8. Gil A, Oyaguez I, Carrasco P, Gonzalez A. Hospital admissions for pertussis in Spain, 1995-1998. Vaccine 2001; 19:4791-4.
9. Crowcroft NS, Booy R, Harrison T, Spicer L, Britto J, Mok Q, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 2003; 88:802-6.
10. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22:628-34.
11. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004; 23:246-52.
12. Rendi-Wagner P, Kundi M, Mikolasek A, Vecsei A, Fruhwirth M, Kollaritsch H. Hospitalbased active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 2006; 24:5960-5.
13. Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 2007; 26:31-5.
14. Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics 2008; 121:484-92.
15. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001; 7:526-8.
16. Annual report on commmunicable diseases in Europe: Report on the status of communicable diseases in the EU and EEA/EFTA countries. Amato-Gauci A and Ammon A, 2007. European Centre for Disease Prevention and Control.
17. Strebel P, Nordin J, Edwards K, Hunt J, Besser J, Burns S, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183:1353-9.
18. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000; 6:348-57.
19. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis 2000; 182:1409-16.
20. Güris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230-7.
21. de Greeff SC, Dekkers ALM, Teunis PF, Rahamat-Langendoen JC, Mooi FR, de Melker HE. Seasonal patterns in time series of pertussis in The Netherlands. Submitted 2009.
22. Nagel J, de GS, Schijf-Evers D. Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. Dev Biol Stand 1985; 61:325-30.
23. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, Elvers LH, Berbers GA, van Der Zee A, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38:800-6.
24. van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. J Infect Dis 1996; 174:89-96.
25. Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9:866-83.
26. Storsaeter J, Wolter J, Locht C. Pertussis vaccines. In: Locht C, ed. First ed. Horizon Bioscience, Norfolk UK 2007; 245-88.
27. Pittman M. History of the development of pertussis vaccine. Dev Biol Stand 1991; 73:13-29.
28. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334:341-8.
29. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55.
30. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350:1569-77.
31. Ibsen PH, Petersen JW, Heron I. Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine. Vaccine 1993; 11:318-22.
32. Ashworth LA, Robinson A, Irons LI, Morgan CP, Isaacs D. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children. Lancet 1983; 2:878-81.
33. Thalen M, van der Ark A, van den Ijssel J, van Straaten I, Jansen D, Beuvery C, et al. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine 2008; 26:653-63.
34. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96:548-57.
35. Steinhoff MC, Reed GF, Decker MD, Edwards KM, Englund JA, Pichichero ME, et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 1995; 96:567-70.
36. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606-12.
37. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003;22: 22-27.
38. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6:364-71.
39. Berbers GAM, Jones N. Serological surveillance of the effect of the changes to pertussis vaccines in the NIP from 2004 till 2008. Switch from whole cell to acellular vaccine in children of 1 year of age. RIVMreport 240012001/2008, 1-59, 2008. National Institute for Public Health and the Environment. RIVM Report 210021008/2008.
40. Anonymus. Summary of Notifiable Diseases - United States, 2006. MMWR 2008; 55:1-94.
41. Ramsay ME, Farrington CP, Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 1993; 111:41-8.
42. Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Commun Dis Rep CDR Rev 1992; 2:152-4.
43. Njamkepo E, Rimlinger F, Thiberge S, Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine. 2002;20: 1290-1294.
44. Kimura M, Kuno-Sakai H. Immunization system in Japan: its history and present situation. Acta Paediatr Jpn 1988; 30:109-26.
45. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24:58-61.
46. Aoyama T, Iwata T, Iwai H, Murase Y, Saito T, Akamatsu T. Efficacy of acellular pertussis vaccine in young infants. J Infect Dis 1993; 167:483-6.
47. Broutin H, Rohani P, Guegan JF, Grenfell BT, Simondon F. Loss of immunity to pertussis in a rural community in Senegal. Vaccine 2004; 22:594-6.
48. Versteegh FG, Schellekens JF, Nagelkerke AF, Roord JJ. Laboratory-confirmed reinfections with Bordetella pertussis. Acta Paediatr 2002; 91:95-7.
49. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term Follow-up of Swedish Children Vaccinated With Acellular Pertussis Vaccines at 3, 5 and 12 Months of Age Indicates the Need for a Booster Dose at 5 to 7 Years of Age. Pediatrics 2006; 118:978-84.
50. Mills KH. Immunity to Bordetella pertussis. Microbes Infect 2001; 3:655-77.
51. Carbonetti NH. Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease. Curr Opin Pharmacol 2007; 7:272-8.
52. Miller E, Rush M, Ashworth LA, Coleman TJ, Rossini J, Ahmed OA, et al. Antibody responses and reactions to the whole cell pertussis component of a combined diphtheria/tetanus/pertussis vaccine given at school entry. Vaccine 1995; 13:1183-6.
53. http://www.ssi.dk/graphics/euvac/vaccination/pertussis.html. 2009.
54. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001; 147:2885-95.
55. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 2004; 22:2122-8.
56. Fingermann M, Fernandez J, Sisti F, Rodriguez ME, Gatti B, Bottero D, et al. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine 2006; 24:3513-21.
57. Watanabe M, Nagai M. Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection. J Health Science 2002; 48:560-4.
58. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96:557-66.
59. Hallander HO, Gustafsson L, Ljungman M, Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 2005; 23:5359-64.
60. Halperin SA. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J 2005; 24:141-6.
61. Kuno-Sakai H., Kimura M, Safety and efficacy of acellular pwertussis vaccine in Japan, evaluated by 23 years of its use for routine immunazation. Pediatrics Int 2004;46:650-655.
62. Kimura M, Kuno-Sakai H. Developments in pertussis immunization in Japan. Lancet 1990; 336:30-2.
63. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24:10-8.
64. de Greeff SC, Schellekens J, Mooi F, de Melker H. Pertussis incidence in the Netherlands after introduction of an acellular booster vaccination at 4 years of age. Eurosurveillance Wkly 2004; 8.
65. Guiso N, Njamkepo E, Vié le Sage F, Zepp F, Meyer CU, Abitbol V, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25:1390-7.
66. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007; 26:806-10.
67. Quinn HE, McIntyre P. B. Pertussis epidemiology in Australia over the decade 1995-2005 - trends by region and age group. Commun Dis Intell 2007; 31:205-15.
68. Galanis E, King AS, Varughese P, Halperin SA. Changing epidemiology and emerging risk groups for pertussis. CMAJ 2006; 174:451-2.
69. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004; 190:535-44.
70. Edelman K, He Q, Mäkinen J, Sahlberg A, Haanperä M, Schuerman L, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007; 44:1271-7.
71. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004; 38:591-4.
72. de Greeff SC, Schellekens JFP, Mooi FR, de Melker HE. Pertussis in the Netherlands, 2001-2003. RIVM Report 1285071010/2003. 2003. RIVM. Ref Type: Report.
73. Shinall MC, Jr, Peters TR, Zhu Y, Chen Q, Poehling KA. Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics 2008; 122:1021-6.
74. Booy R, Aitken SJ, Taylor S, Tudor-Williams G, Macfarlane JA, Moxon ER, et al. Immunogenicity of combined diphtheria, tetanus and pertussis vaccine given at 2, 3 and 4 months versus 3, 5 and 9 months of age. Lancet 1992; 339:507-10.
75. Geurtsen J, Vandebriel RJ, Gremmer ER, Kuipers B, Tommassen J, van der Ley P. Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines. Microbes Infect 2007; 9:1096-103.
76. van der Ley P, Steeghs L. Lessons from an LPS-deficient Neisseria meningitidis mutant. J Endotoxin Res 2003; 9:124-8.
77. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006; 7:65.
78. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16.
79. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6.
80. Carbonetti NH, Artamonova GV, Van Rooijen N, Ayala VI. Pertussis Toxin Targets Airway Macrophages to Promote Bordetella pertussis Infection of the Respiratory Tract. Infect Immun 2007; 75:1713-20.
81. Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 2005; 115:3594-601.
82. Anderson P, Ingram DL, Pichichero ME, Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J 2000; 19:589-91.
83. Peppoloni S, Pizza M, De Magistris MT, Bartoloni A, Rappuoli R. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Physiol Chem Phys Med NMR 1995; 27:355-61.
84. Di Tommaso A, De Magistris MT, Bugnoli M, Marsili I, Rappuoli R, Abrignani S. Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infect Immun 1994; 62:1830-4.
85. Hewlett EL. Acellular pertussis trial. Pediatrics 1996; 98:800.
86. Carbonetti NH, Artamonova GV, Andreasen C, Bushar N. Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect Immun 2005; 73:2698-703.
87. Hethcote HW. Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Math Biosci 1999; 158:47-73.
88. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004; 22:3154-65.
89. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5:74.
90. de Greeff SC, Lugnér AK, van den Heuvel DM, Mooi FR, de Melker HE. Economic analysis of pertussis illness in the Dutch population: Implications for current and future vaccination strategies. Vaccine 2009; In press.
91. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-9.
92. Skowronski DM, Pielak K, Remple VP, Halperin BA, Patrick DM, Naus M, et al. Adult tetanus, diphtheria and pertussis immunization: knowledge, beliefs, behavior and anticipated uptake. Vaccine 2004; 23:353-61.
93. Wilder-Smith A, Boudville I, Earnest A, Heng SL, Bock HL. Knowledge, attitude and practices with regard to adult pertussis vaccine booster in travelers. J Travel Med 2007; 14:145-50.
94. Wicker S, Zielen S, Rose MA. Attitudes of healthcare workers toward pertussis vaccination. Expert Rev Vaccines 2008; 7:1325-8.
95. Kowalzik F, Barbosa AP, Fernandes VR, Carvalho PR, Avila-Aguero ML, Goh DY, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26:238-42.
96. de Greeff SC, Mooi FR, de Melker HE. Sources of infection of pertussis in infants too young to be vaccinated. Book of abstracts of the 25th annual meeting of the European Society for Paediatric Infectious Diseases; 2007; Porto, Portugal; 2007. Abstract 95. 2007; Ref Type: Abstract.
97. Belloni C, De Silvestri A, Tinelli C, Avanzini MA, Marconi M, Strano F, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003; 111:1042-5.
98. Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655-60.
99. McIntyre P, Wood N, Marshall H,Roberton D. Immunogenicity of birth and one month old acellular pertussis (Pa) vaccine. 47th ICAAC. Chicago 17-20 September 2007. 2007; Ref Type: Abstract.
100. Halasa NB, O'Shea A, Shi JR, Lafleur BJ, Edwards KM. Poor Immune Responses to a Birth Dose of Diphtheria, Tetanus and Acellular Pertussis Vaccine. J Pediatr 2008 153:327-32.
101. Siegrist CA. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus and acellular pertussis immunization. J Pediatr 2008; 153:305-7.
102. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007; 25:391-8.
103. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007; 7:614-24.
104. Theilen U, Johnston ED, Robinson PA. Rapidly fatal invasive pertussis in young infants - how can we change the outcome? BMJ 2008; 337:343.